Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia

NCT01239992 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped negative endpoint study resulting in withdrawal of study drug

Conditions

Hyperlipoproteinemia
Metabolic Syndrome

Interventions

DRUG: Niacin/ Laropiprant

Sponsor

Ludwig-Maximilians - University of Munich